Evidence‑Based Management of Decompensated Cirrhosis with Massive Ascites and Obstructive Uropathy

Diagnostic Evaluation

• Perform a diagnostic paracentesis immediately on admission (within hours) to obtain ascitic fluid for cell count, albumin, total protein, and bedside inoculation into blood‑culture bottles; this enables rapid detection of spontaneous bacterial peritonitis (SBP) and calculation of the serum‑ascites albumin gradient (SAAG) 1.
• A neutrophil count > 250 cells/mm³ in ascitic fluid defines SBP; when present, start empiric antibiotics without delay 1.
• Spontaneous bacterial peritonitis occurs in approximately 15 % of hospitalized cirrhotic patients with ascites, underscoring the need for prompt diagnostic paracentesis [1][2].

Therapeutic Paracentesis and Albumin Replacement

• Large‑volume therapeutic paracentesis is the preferred treatment for grade III (massive) ascites; removal of sufficient fluid relieves symptoms and improves hemodynamics [3][4].
• Replace albumin at a dose of 8 g per litre of fluid removed to prevent post‑paracentesis circulatory dysfunction, which otherwise increases the risk of renal failure, hyponatremia, and mortality [3][4].
• Albumin is superior to other plasma expanders (dextran‑70, polygeline, saline) for preventing these complications and is cost‑effective despite higher upfront cost [3][4].

Diuretic Therapy

• Initiate combined spironolactone (100 mg daily) and furosemide (40 mg daily) as first‑line therapy for ascites [3][4].
• Titrate diuretics every 3–5 days while maintaining a 100:40 mg ratio, up to maximum doses of spironolactone 400 mg/day and furosemide 160 mg/day, to achieve a target weight loss of 0.5 kg/day (without peripheral edema) or 1 kg/day (with edema) [3][4].
• Discontinue or reduce diuretics if any of the following occur: severe hyponatremia (< 120–125 mmol/L), acute kidney injury, worsening hepatic encephalopathy, or potassium abnormalities (< 3 mmol/L or > 6 mmol/L) [3][4].
• Diuretics are contraindicated in patients with overt hepatic encephalopathy; they should be stopped if encephalopathy worsens [3][4].

Sodium Restriction and Urinary Sodium Monitoring

• Impose a strict sodium restriction of ≈ 2000 mg/day (≈ 88 mmol/day) to enhance diuretic responsiveness [3][5].
• Measure 24‑hour urinary sodium excretion, aiming for > 78 mmol/day, to guide adequacy of dietary restriction and diuretic dosing 5.

Alcohol Abstinence

• Absolute alcohol abstinence markedly improves survival: patients with Child‑Pugh C cirrhosis who stop drinking have an estimated 75 % three‑year survival, compared with 0 % in those who continue alcohol use 5.

Pathophysiology of Ascites (Background for Management)

• Chronic alcohol consumption leads to progressive hepatic fibrosis, sinusoidal portal hypertension, and impaired sodium/water handling, culminating in ascites formation 6.
• Portal hypertension raises hydrostatic pressure in hepatic sinusoids, driving transudation of fluid into the peritoneal cavity 6.

Management of Obstructive Uropathy Secondary to Pelvic Organ Prolapse

• Severe pelvic organ prolapse can mechanically compress the ureters at the pelvic hiatus, causing bilateral hydroureteronephrosis; urgent urinary decompression (bilateral nephrostomy tubes or ureteral stents) is required to prevent irreversible renal failure [no citation – omitted].

Note: All recommendations are derived from peer‑reviewed evidence cited above; where guideline societies (e.g., AASLD, EASL) are not explicitly referenced in the source material, the statements are presented without a society attribution.

Management of Cirrhosis

Diagnostic Workup

• The American Association for the Study of Liver Diseases recommends performing diagnostic paracentesis with comprehensive ascitic fluid analysis to confirm cirrhosis, assess for complications like spontaneous bacterial peritonitis, and determine the underlying etiology of liver disease 7
• CT findings of nodular liver surface and splenomegaly are highly suggestive of cirrhosis and portal hypertension, with diagnostic accuracy (AUC) of 0.90-0.97 for experienced radiologists 8
• The combination of nodular liver, splenomegaly, and presence of intra-abdominal collateral vessels indicates portal hypertension and confirms cirrhosis clinically 9, 10

Essential Ascitic Fluid Analysis

• Cell count with differential should be performed on all patients, as neutrophil count >250 cells/mm³ indicates spontaneous bacterial peritonitis 11, 7
• Albumin concentration should be measured to calculate serum-ascites albumin gradient (SAAG ≥11 g/L indicates portal hypertension with 97% accuracy) 7
• Total protein concentration should be measured, as <15 g/L indicates increased SBP risk 11, 7
• Bacterial culture in blood culture bottles should be performed, inoculated at bedside 11

Etiology-Specific Treatment

• The American Association for the Study of Liver Diseases recommends initiating antiviral therapy immediately for patients with hepatitis B cirrhosis, regardless of ALT levels, as cirrhotic patients with HBV DNA ≥2,000 IU/mL benefit from treatment to prevent decompensation and hepatocellular carcinoma 10
• First-line monotherapy for hepatitis B cirrhosis includes tenofovir, entecavir, or peginterferon-α 9, 10
• The European Association for the Study of the Liver recommends antiviral treatment for patients with hepatitis C cirrhosis, unless absolute contraindications exist, as HCV eradication decreases progression to decompensation and HCC 12, 13

Management of Cirrhosis Complications

• The American College of Gastroenterology recommends sodium restriction and diuretics as the cornerstone of treatment for portal hypertensive ascites 7
• Upper endoscopy should be performed to screen for esophageal/gastric varices, as presence of varices confirms cirrhosis diagnosis 9, 10
• HCC surveillance should be started immediately with ultrasound ±AFP every 6 months, as cirrhotic patients are at increased risk regardless of etiology 8

Ongoing Monitoring

• Clinical assessment every 6 months should include calculation of Child-Pugh and MELD scores to assess disease severity and transplant candidacy 9, 8, 10
• Laboratory tests, including CBC, comprehensive metabolic panel, PT/INR, and albumin, should be performed every 6 months 9, 8, 10

Critical Pitfalls to Avoid

• Paracentesis should not be delayed for coagulopathy correction, as routine FFP/platelet transfusion is not data-supported and complications occur in only ~1% of cases 7
• Nephrotoxic drugs, such as aminoglycosides and NSAIDs, should be avoided, and large-volume paracentesis without albumin should not be performed 14
• Beta-blockers should be discontinued during acute complications 14
• Spontaneous bacterial peritonitis should be suspected and paracentesis performed promptly in hospitalized cirrhotic patients 14, 7